DPF3, a chromatin remodeling cofactor significantly downregulated in breast cancer tissue, promoting the proliferation of breast cancer cells, has been suggested as a novel therapeutic target for breast cancer therapy [78]. This evidence concerns the gene DPF3 and breast carcinoma.